SYNDROMIC LEVEL MULTIPLE TARGETS IN A SINGLE-WELL ARRAY TEST.
New assays powered by the PathogenDx D3 Array will deliver a more flexible, efficient and lower cost path to detection.
CLINICAL DIAGNOSTICS WITH A DIFFERENCE
PathogenDx is harnessing the power of its D3 Array to provide RUO Assays that deliver more actionable information to reduce time in clinical decision-making. Discover how this new technology aids in selection and optimization of therapy and treatment plans.
In each well of the 96-well plate, PathogenDx uses a proprietary process to print up to 128 probes, each capable of identifying a different pathogen, variant or serotype—witht novel binding of DNA when pathogens are present.
COMING SOON
No culturing. Rapid, accurate information. PathogenDx’s new comprehensive UTI RUO assay will soon provide critical information to inform and guide targeted treatment for patients with complicated UTIs.
Enhanced analytical sensitivity with detection of a wide range of bacterial and fungal pathogens, as well as antibiotic resistance markers in the same test. This panel of tests in a D3 array offers a highly multiplexed, syndromic approach versus smaller separate panels or individual serial qPCR multiplex assay.
KEY FEATURES
Rapid Diagnosis – Clinically actionable results in hours not days. Enables earlier selection of the ‘right’ therapy leading to optimal clinical outcomes.
Multiplexed Panel – Analytically sensitive, highly multiplexed panel of assays, in a single test, simultaneously testing for multiple pathogens. UTI assay identifies 25+ specific pathogen targets and 13+ antibiotic resistance classes/genes.
Reduced Labor and Costs – Reduced reaction time and labor. Scalable, easy to implement, with multiple target probes included in a single-well array that delivers a more affordable assay and time-sensitive clinical information.
ASSAYS FOR COVID-19 (EUA)
During the pandemic, PathogenDx rapidly developed DetectX-Rv to contribute to viral detection. Differentiating Corona-like-viruses from SARS-CoV-2 and delivering industry leading accuracy, DetectX-Rv was authorized for emergency use by the FDA under an EUA for use by authorized laboratories.
And with the D3 Array’s unique spatial architecture, came the opportunity to develop multiplexed assays for the simultaneous detection of SARS-CoV-2 variants. DetectX-Cv detects all major variants with results in 4 hours after a positive sample.
OTHER D3 ARRAY RUO ASSAYS IN THE WORKS.
PathogenDx D3 Array’s unique spatial architecture enables comprehensive, multiplexed assays for the simultaneous detection of a wide range of pathogens associated with Women’s Health including the detection of HPV variants, vaginal infections, and STIs. The D3 Array format, with enhanced probe binding, single gene copy sensitivity, competitive economies and rapid time-to-result, is well suited for this need.
The D3 Array promotes confidence in results and better patient care. The simultaneous detection of a wide range of pathogens aids in rapid diagnosis and treatment. PathogenDx is committed to supporting women’s health initiatives by providing accurate and sensitive tests. Learn more »
Rapid, multiplexed detection of the causative agent(s) of bloodborne infections and the bacteria’s antimicrobial susceptibility are critical for the selection of treatment options. With traditional ID/AST testing, time to result can be days and costly antibiotics are often prescribed until the specific pathogen can be identified and treatment optimized.
PathogenDx’s D3 Array has the potential to provide highly-multiplexed detection and susceptibility information in a low-cost, rapid format that will significantly increase quality of care by providing critical information to physicians, reducing morbidity and mortality in bacteremic patients. Watch for such future products. Learn more »
